Skip to main content

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Objective

“HAP2” aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of hospital-acquired pneumonia (HAP) and develop precision medicine in infectious diseases.
HAP is an infectious disease of major concern in the world, and the most frequent cause of hospital-acquired infections with 500,000 episodes being treated every year in Europe. Despite the development of European recommendations, the incidence remains high, with dramatic medical consequences: existing therapies and preventive measures do not result in the expected favourable outcome (clinical cure and survival) for 30% of patients. HAP are moreover the main cause of antibiotic consumption in European hospitals and are increasingly induced by drug-resistant pathogens. New, alternative and more effective host-targeted strategies are therefore urgently needed to fight antibiotic resistance.
The ambition of “HAP2” is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, we propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis. “The HAP2” project will reach two ground-breaking objectives in the field of bacterial infections: first the development of host-targeted approaches for the prevention and the treatment of a severe bacterial infection through the supplementation of the IL-12/IFN-γ axis which is defective in patients at risk of pneumonia; second the development of a clinico-biological score based on an integrative assessment of the host-pathogen interactions and genetic variation, to predict the course of HAP and the response to treatment. Our interdisciplinary consortium, bringing together 10 partners from academia and industry with expertise in clinical trials, immunology, microbiome analysis, omics and social sciences is uniquely placed to achieve this ambition within this 5-year project.

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2019-Two-Stage-RTD

Coordinator

CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Net EU contribution
€ 3 642 770,25
Address
Allee De L'ile Gloriette 5
44093 Nantes
France

See on map

Region
Pays de la Loire Pays de la Loire Loire-Atlantique
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00

Participants (11)

NANTES UNIVERSITE
France
Net EU contribution
€ 1 273 025,00
Address
1 Quai De Tourville
44000 Nantes

See on map

Region
Pays de la Loire Pays de la Loire Loire-Atlantique
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA
Spain
Net EU contribution
€ 802 411,25
Address
Carrer Rossello 149
08036 Barcelona

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Other funding
€ 0,00
Third-party

Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.

HOSPITAL CLINIC DE BARCELONA
Spain
Net EU contribution
€ 38 953,75
Address
Calle Villarroel 170
08036 Barcelona

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Other funding
€ 0,00
UNIVERSITAT ZURICH
Switzerland
Net EU contribution
€ 1 510 587,50
Address
Ramistrasse 71
8006 Zurich

See on map

Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Greece
Net EU contribution
€ 96 081,25
Address
6 Christou Lada Str
10561 Athina

See on map

Region
Κεντρικός Τομέας Αθηνών Aττική Αττική
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN
United States
Net EU contribution
€ 322 837,50
Address
South Street 3003 1068
46109 1274 Ann Arbor

See on map

Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
HOSPICES CIVILS DE LYON
France
Net EU contribution
€ 315 227,50
Address
Quai Des Celestins 3
69002 Lyon

See on map

Region
Auvergne-Rhône-Alpes Rhône-Alpes Rhône
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Other funding
€ 0,00
STICHTING RADBOUD UNIVERSITEIT

Participation ended

Netherlands
Net EU contribution
€ 0,00
Address
Houtlaan 4
6525 XZ Nijmegen
Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00
NEUMEDICINES INC.

Participation ended

United States
Net EU contribution
€ 732 127,50
Address
10426 Helendale Ave
91042 Tujunga Ca
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 0,00
BIG DATA SANTE
France
Net EU contribution
€ 477 328,75
Address
Rue Condorcet
44100 Nantes

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Pays de la Loire Pays de la Loire Loire-Atlantique
Activity type
Other
Other funding
€ 0,00
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands
Net EU contribution
€ 785 000,00
Address
Geert Grooteplein 10 Zuid
6525 GA Nijmegen

See on map

Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Other funding
€ 0,00